A Plus Biotechnology held a pre-listing performance presentation yesterday (6th), announcing plans to list in mid-June. The company’s developed "Precise Customized Surgical Guidance Tools" (PSI) are expected to be promoted for use in more orthopedic surgeries, further expanding the product's depth and application range.
Chairman Li Siming stated that the company, leveraging its globally innovative technology specifically designed for the curvature of Asian bones, has successfully disrupted traditional products designed for Western body types. Their orthopedic implants, such as bone plates and screws, are designed with a locking mechanism that better suits the Asian body shape and made with high-quality titanium alloy material. A Plus holds over 30% of the market share for self-paid locking bone plates in Taiwan, with more than 200 hospitals using their products monthly.
A Plus Biotechnology’s revenue structure is primarily based on the Taiwan market, which accounts for 76.8%, followed by China at 20.9%, and Southeast Asia and global markets at 2.3%. The company’s product structure includes trauma and correction products such as bone plates, screws, and guidance tools, which contribute 82.97% of revenue, while agency products like artificial bones, hemostatic powders, and disposable surgical instruments account for 17.03%.
Li Siming emphasized that A Plus’s rapid market leadership is mainly due to its breakthrough design and strong technological R&D capabilities.
The company not only has a complete trauma medical product line but also integrates advanced technologies such as medical image analysis, 3D printing, and biomechanics to develop the Precise Customized Surgical Guidance Tools (PSI).
This tool constructs a 3D bone model of the patient, accurately analyzes fracture and deformity sites, and assists surgeons in making meticulous pre-surgical plans and judgments. This ensures the surgery aligns with the plan, improving accuracy during surgery and significantly increasing success rates and efficiency. The application of this technology has expanded to include osteotomy correction, joint replacement, and spinal surgeries.
General Manager Luo Xiangwei stated that the company has successfully established an extensive and stable sales channel, collaborating with distributors familiar with the market to develop customers and expand the market. Additionally, by leveraging its sales network from self-manufactured trauma products, the company has introduced agency biochemical products, significantly improving sales efficiency. In the future, A Plus is expected to obtain more opportunities to represent biochemical medical and surgical peripheral products, further extending its product offerings beyond orthopedics to other specialties.
Resource: 愛派司 下月中旬掛牌
